SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing a massive surge driven by intense short-squeeze dynamics and investor anticipation of pivotal phase 3 clinical trial results. The community is focused on the impending 80th event milestone, which will trigger trial unblinding and serves as a major catalyst fueling speculation about potential buyout interest from big pharma.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is currently facing intense selling pressure and bearish sentiment, with investors debating whether the stock is a value opportunity or caught in a structural downtrend amid ongoing concerns over management execution and adtech sector volatility. Community discussion is heavily focused on the company's lack of substantive news at the Cannes Lions event, skepticism toward the CEO's leadership, and the stock's persistent underperformance relative to broader market momentum.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense community debate as the stock faces downward pressure despite recent inclusion in the Russell indexes and strategic drone sector partnerships. Investors are polarized between those viewing the current pullback as a liquidity-driven shakeout before a potential institutional run and those concerned by ongoing share dilution and sustained short interest.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing a surge in volatility and trader interest as the community reacts to an expanding robotaxi partnership with Uber and Nuro, alongside ongoing discussions about significant workforce reductions and structural cost-saving initiatives. Investors are closely monitoring a massive spike in borrow rates and low share availability, fueling widespread speculation among community members regarding the potential for a short squeeze.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack in the Box is trending due to its recent agreement to sell Del Taco for 115 million, a move community members are debating as either a necessary step to slash debt or a massive failure in value destruction. Retail investors remain hyper-focused on the company's high short interest and low float, fueling speculation of a potential short squeeze as participants contrast the brand's turnaround efforts against its ongoing struggle with high debt levels.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending after introducing a new capital framework that allows the company to sell portions of its Bitcoin holdings to fund share repurchases and dividends, prompting intense debate among investors over whether this signals sustainable financial flexibility or a desperate shift away from its core 'HODL' strategy. Community discussion remains polarized, with bulls viewing the move as a strategic move to manage capital during market volatility, while bears interpret the monetization program as a bearish indicator and a reversal of the company's long-term Bitcoin accumulation thesis.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is seeing significant market enthusiasm as the company secures multiple high-value contracts for its small modular reactors and wide-body aircraft engines. Community sentiment remains largely bullish, with investors focusing on the firm's strategic expansion in defense and nuclear energy as key catalysts for long-term growth.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as investors speculate that the company's decision to discontinue internal discovery programs and close its Alabama research facility signals a strategic pivot toward becoming an acquisition target. The community is actively debating whether this cost-cutting move reflects a lack of long-term vision or a deliberate consolidation of assets to make the company a more attractive bolt-on for potential suitors, with many analysts and retail traders closely watching clinical progress with its HAE portfolio for further validation.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to the company's recent move to repurchase convertible debt, which many in the community interpret as a strategic signal of management's confidence ahead of potential catalysts. While the stock has faced downward pressure, the community is focused on the upcoming J-code activation, anticipated EMA regulatory developments, and potential milestone payments from the Novo Nordisk partnership as key drivers for long-term value.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is experiencing heightened volatility and intense community discussion following notable insider selling by senior executives, while investors debate the impact of potential index inclusion and the timeline for BPL-003 clinical trials. Sentiment remains divided between long-term bulls highlighting the company's cash runway and clinical pipeline versus cautious traders reacting to inconsistent price action and concerns over management communication.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tamara A Favorito Expands Holdings With $51K Zevra Therapeutics Stock Options Acquisition

A notable acquisition unfolded on June 18, as Favorito, Director at Zevra Therapeutics (NASDAQ:ZVRA), reported the acquisition of stock options for 30,000 shares in an SEC filing.
What Happened: A Form 4 filing from theread more...

Corey M. Watton Seizes Opportunity: Acquires $51K Worth Of Zevra Therapeutics Stock Options

In a recent SEC filing, it was disclosed that Corey M. Watton, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), made a noteworthy acquisition of company stock options on June 18,.
What Happened: A Form 4 filing fromread more...

A Noteworthy Decision By Thomas Anderson As Acquires $51K In Zevra Therapeutics Stock Options

In a new SEC filing on June 18, it was unveiled that Anderson, Director at Zevra Therapeutics (NASDAQ:ZVRA), acquired stock options for 30,000 shares.
What Happened: Uncovered in a Form 4 filing on Thursday with theread more...

Alicia Secor Takes A Bullish Stance, Acquiring $51K Worth Of Zevra Therapeutics Stock Options

A noteworthy insider acquisition was disclosed on June 18, as Secor, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), reported the acquisition of stock options for 30,000 shares.
What Happened: Uncovered in a Form 4read more...

Douglas W Calder Makes Strategic Play: Invests $51K In Zevra Therapeutics Stock Options

In a new SEC filing on June 18, it was unveiled that Calder, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), acquired stock options for 30,000 shares.
What Happened: Calder, Board Member at Zevra Therapeutics,read more...

Big News: Alvin Shih Adds $51K In Zevra Therapeutics Stock Options Io Portfolio

In a new SEC filing on June 18, it was unveiled that Shih, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), acquired stock options for 30,000 shares.
What Happened: In a recent Form 4 filing with the U.S. Securitiesread more...

ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?

Equity

Zevra Therapeutics shares saw a series of positive brokerage actions after the company asked the U.S. Food and Drug Administration to add a new patent for its Miplyffa drug to the Orange Book.

ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug

Zevra said in a statement that it has asked the U.S. Food and Drug Administration to add its new patent for its drug MIPLYFFA to its official list.


Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +184.36% and +15.51%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -29.46% and -15.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$14.01
Prev Close	$13.52
Open	$13.53
Dividend Yield	0.00%
50-Day Moving Average	$11.28
Beta	0.84
Avg. Volume	1.97M
PE Ratio	6.28

52-Week High	$14.27
52-Week Low	$7.16
Market Capitalization	$799.24M
EPS (Annual)	$1.35
Price to Book	3.88
Revenue Per Employee	$1.75M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZVRAZevra Therapeutics Inc

Latest ZVRA News